MG-101 (Calpain Inhibitor I, ALLN)
(Synonyms: ALLN钙蛋白酶抑制剂,Ac-LLnL-CHO, MG-101, MG101,N-Acetyl-L-leucyl-L-leucyl-L-norleucinal, N-Acetyl-Leu-Leu-Nle-al,Calpain Inhibitor I) 目录号 : GC12527
MG-101 (Calpain Inhibitor I, ALLN)是半胱氨酸蛋白酶 的抑制剂，抑制钙蛋白酶I，钙蛋白酶II，组织蛋白酶B和组织蛋白酶L，其Ki值分别为90，220，150和500pM。
Cas No.:110044-82-1
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
MG-101 (Calpain Inhibitor I, ALLN) also known as Calpain Inhibitor I, selectively inhibits various cysteine proteases, including calpain I, calpain II, cathepsin B, and cathepsin L. The corresponding Ki values for these enzymes are 90pM, 220pM, 150pM, and 500pM[1]. Calpains are a family of calcium-dependent cysteine proteases[2] that play important roles in many cellular processes. MG-101 has been shown to protect against neuronal damage in ischemic stroke models by inhibiting calpain activity [3]. Additionally, MG-101 can inhibit the activity of the SARS-CoV-2 virus[4].
In vitro, pre-treatment of iBREC (immortalized bovine retinal endothelial cells) with MG-101 (20nM) for 4 hours, followed by stimulation with VEGF (250µg/ml) for 4 hours, significantly increased the accumulation of aflibercept within the cells, inhibited its degradation, and suppressed lysosomal protease activity[5]. In primary rat retinal neurons treated with MG-101 (2.5–7.5µM) for 6–24 hours, MG-101 significantly reduced cell viability, induced cell death, and caused retinal neuronal death through necrosis and apoptosis[6].
In vivo, pre-treatment of mice with MG-101 (10mg/kg) via intraperitoneal injection, followed by ischemic preconditioning (IPC), significantly inhibited the degradation of cardiac myosin-binding protein C (cMyBP-C) induced by myocardial ischemia/reperfusion (I/R) injury and promoted its phosphorylation[7]. In rats, MG-101 (20mg/kg) administered via intraperitoneal injection significantly improved biochemical marker levels in serum and brain tissue and reduced the number of apoptotic cells, showing protective effects against neuroapoptotic cell damage caused by CuO-NP and I/R[8].
References:
[1] Li SZ, Zhang HH, Zhang JN, et al. ALLN hinders HCT116 tumor growth through Bax-dependent apoptosis. Biochem Biophys Res Commun. 2013 Jul 26;437(2):325-30.
[2] Hamidi R, Ataei F, Hosseinkhani S. Inhibition of noncaspase proteases, calpain and proteasome, via ALLN and Bortezomib contributes to cell death through low degradation of pro-/anti-apoptotic proteins and apoptosis induction. Med Oncol. 2022 Jun 18;39(9):125.
[3] Matsui Y, Kanou T, Matsui T, et al. Protective Effect of Calpain Inhibition During Cold Ischemia on Ischemia-reperfusion Injury After Lung Transplantation. Transplantation. 2023 Sep 1;107(9):1945-1954.
[4] Narayanan A, Narwal M, Majowicz SA, et al. Identification of SARS-CoV-2 inhibitors targeting Mpro and PLpro using in-cell-protease assay. Commun Biol. 2022 Feb 25;5(1):169.
[5] Deissler HL, Lang GK, Lang GE. Fate of the Fc fusion protein aflibercept in retinal endothelial cells: competition of recycling and degradation. Graefes Arch Clin Exp Ophthalmol. 2019 Jan;257(1):83-94.
[6] Li N, Shang L, Wang SC, et al. The Toxic Effect of ALLN on Primary Rat Retinal Neurons. Neurotox Res. 2016 Oct;30(3):392-406.
[7] Liang C, Aisa Z, Sun L, et al. Cardiac ischemic preconditioning promotes cMyBP-C phosphorylation by inhibiting the calpain-mediated proteolysis. Exp Cell Res. 2023 Dec 15;433(2):113859.
[8] Karimkhani H, Shojaolsadati P, Yiğitbaşı T, et al. The effect of calpain inhibitor-I on copper oxide nanoparticle-induced damage and cerebral ischemia-reperfusion in a rat model. Biomed Pharmacother. 2024 May;174:116539.
MG-101 (Calpain Inhibitor I, ALLN)是半胱氨酸蛋白酶 的抑制剂，抑制钙蛋白酶I，钙蛋白酶II，组织蛋白酶B和组织蛋白酶L，其Ki值分别为90，220，150和500pM[1]。钙蛋白酶是一类依赖钙离子的半胱氨酸蛋白酶家族[2]，在许多细胞过程中发挥重要作用MG-101抑制钙蛋白酶活性已被证明在缺血性中风模型中对神经元损伤具有保护作用[3]。MG-101还能抑制SARS-CoV-2病毒活性[4]。
在体外，MG-101（20nM）预处理iBREC（牛视网膜内皮细胞）4小时后，再以VEGF（250µg/ml）刺激4小时，可显著增加细胞内aflibercept的积累，同时抑制其降解，并抑制溶酶体蛋白酶活性[5]。MG-101（2.5–7.5µM）处理原代大鼠视网膜神经元6–24小时，MG-101显著降低细胞活力，诱导细胞死亡，而且MG-101可通过坏死和凋亡诱导视网膜神经元死亡[6]。
在体内，MG-101（10mg/kg）通过腹腔注射预处理小鼠后，再进行缺血预处理（IPC），显著抑制了心肌缺血/再灌注（I/R）损伤诱导的心脏肌球蛋白结合蛋白C（cMyBP-C）的降解，并促进了其磷酸化水平的提高[7]。MG-101（20mg/kg）通过腹腔注射给予大鼠，用于处理CuO-NP诱导的损伤和脑缺血/再灌注损伤。MG-101显著改善了血清和脑组织中的生化标志物水平，减少了凋亡细胞数量，对CuO-NP和I/R诱导的神经细胞损伤具有保护作用[8]。
| Cell experiment [1]: | |
|
Cell lines |
Primary rat retinal neurons |
|
Preparation Method |
Primary retinal neurons were cultured from the retinas of newborn Sprague–Dawley rats (1-day old). The retinas were incubated at 37°C for 20min in a papain solution (2mg/ml). Retinal neurons were mechanically dissociated and plated at a density of 1.2×10⁵ cells per cm² onto poly-D-lysine (0.01mg/ml)-coated flasks or multi-well plates. The cells were cultured in a neurobasal medium supplemented with 2% B27 in a humidified 5% CO₂ incubator at 37°C, with culture media changed every 2 days. Primary retinal neurons were treated with MG-101 (1, 2.5, 5, 7.5μM) for 6, 12, and 24 h. |
|
Reaction Conditions |
1, 2.5, 5, 7.5µM; 6, 12, and 24 hours |
|
Applications |
MG-101 significantly reduced cell viability of primary retinal neurons at concentrations equal to and higher than 2.5µM, induced cell death, increased LDH release and PI-positive cells, and up-regulated the protein levels of caspase-3. The ratio of Bax/Bcl-2 was raised and Annexin V-positive cells were increased. |
| Animal experiment [2]: | |
|
Animal models |
Male Wistar Albino rats |
|
Preparation Method |
The rats were divided into eight groups. Control group: Given 2mL of physiological saline (SF) by gavage for five days; I/R group: Given 2mL of saline by gavage for five days, followed by induction of an I/R damage model 60 minutes after the last day; CuO-NP group: Given 200mg/kg copper oxide nanoparticles by gavage for five days; CuO-NP+I/R group: Given 200mg/kg copper oxide nanoparticles by gavage for five days, followed by induction of an I/R model 60 minutes after the last day; I/R+ MG-101 group: Given 2mL of saline by gavage for five days, followed by induction of an I/R model 60 minutes after the last day, and then treated with 20mg/kg of the calpain inhibitor MG-101 15 minutes later; CuO-NP+ MG-101 group: Given 200mg/kg copper oxide nanoparticles by gavage for five days, followed by treatment with 20mg/kg of the calpain inhibitor MG-101 15 minutes after the last day; CuO-NP+I/R+MG-101 group: Given 200mg/kg copper oxide nanoparticles by gavage for five days, followed by induction of an I/R model 60 minutes after the last day, and then treated with 20mg/kg of the calpain inhibitor MG-101 15 minutes later. DMSO group: Given 2mL of physiological saline by gavage for five days, followed by induction of an I/R model 60 minutes after the last day, and then treated with a DMSO solution containing the dissolved calpain inhibitor 15 minutes later. |
|
Dosage form |
20mg/kg MG-101; i.p. |
|
Applications |
MG-101 significantly improved biochemical markers and reduced apoptosis in brain tissue, showing protective effects against CuO-NP-induced and I/R-induced brain damage. |
|
References: |
|
| Cas No. | 110044-82-1 | SDF | |
| 别名 | ALLN钙蛋白酶抑制剂,Ac-LLnL-CHO, MG-101, MG101,N-Acetyl-L-leucyl-L-leucyl-L-norleucinal, N-Acetyl-Leu-Leu-Nle-al,Calpain Inhibitor I | ||
| 化学名 | 2-acetamido-4-methyl-N-[4-methyl-1-oxo-1-(1-oxohexan-2-ylamino)pentan-2-yl]pentanamide | ||
| Canonical SMILES | CCCCC(C=O)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C | ||
| 分子式 | C20H37N3O4 | 分子量 | 383.54 |
| 溶解度 | ≥ 19.1mg/mL in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.6073 mL | 13.0364 mL | 26.0729 mL |
| 5 mM | 0.5215 mL | 2.6073 mL | 5.2146 mL |
| 10 mM | 0.2607 mL | 1.3036 mL | 2.6073 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet